For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
5
views
18
references
 Top references
cited by
85
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      2,365
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

          Martin Reck, Delvys Rodriguez-Abreu, Andrew G Robinson … (2016)
          Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1).
          Article 0 comments Cited 2526 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

            Rina Hui, Takayasu Kurata, Silvia Novello … (2018)
            First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial.
            Article 0 comments Cited 2040 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Toxicity and response criteria of the Eastern Cooperative Oncology Group.

              Martin M. Oken, Richard H. Creech, Douglass C. Tormey … (1982)
              Article 0 comments Cited 1253 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: New England Journal of Medicine
                Abbreviated Title: N Engl J Med
                Publisher: Massachusetts Medical Society
                ISSN (Print): 0028-4793
                ISSN (Electronic): 1533-4406
                Publication date (Electronic): June 03 2023
                Affiliations
                [1 ]From Stanford University School of Medicine, Stanford Cancer Institute, Stanford, CA (H.W.); Centre Hospitalier de l’Université de Montréal (M.L.) and McGill University Health Centre (J.D.S.) — both in Montreal; Kanagawa Cancer Center, Yokohama (T.K.), and National Cancer Center Hospital East, Kashiwa (M.T.) — both in Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (S.-H.L.); the National Cancer Center, National Clinical Research Center for Cancer, Cancer...
                Article
                DOI: 10.1056/NEJMoa2302983
                PubMed ID: 37272513
                SO-VID: 68ac17c9-7d88-4569-8e61-f6ef54a1dd71
                Copyright © © 2023
                License:

                http://www.nejmgroup.org/legal/terms-of-use.htm

                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content2,365

                See all similar

                Cited by85

                See all cited by

                Most referenced authors654

                See all reference authors